Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crestor for prevention of recurrent VTE
NCT01164540Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Feb 2011
- Primary completion
- Mar 2013
01
Overview
A Phase 3 trial of rosuvastatin in venous thromboembolism (VTE), sponsored by AstraZeneca. Planned start Feb 2011; status: withdrawn.
02
Drugs
rosuvastatin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01164540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01164540.